Abstract Introduction In a previous report, we demonstrated a favorable trend for supplementation with antithrombin (AT) concentrate at a dosage of 3,000 IU/day over 1,500 IU/day for the treatment of sepsis-associated disseminated intravascular coagulation (DIC) in patients with an AT activity of 70% or less.
← all excerpts
Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey.
2
—
—
The sentences
Since the survival difference did not reach statistical significance, we planned to examine the effects in a larger number of cases with severer disease.